Biological Modification of Arrhythmogenic Substrates by Cell-Free Therapeutics.
Publication Year:
2023
PubMed ID:
37353457
Funding Grants:
Public Summary:
Ventricular arrhythmias (VAs) are dangerous heart rhythm problems that can cause sudden death, especially in people with heart failure or inherited heart diseases. Current treatments like medications, devices, and procedures have limits and can sometimes harm heart cells. New therapies using cell treatments and tiny particles called exosomes show promise because they might protect heart cells, reduce inflammation, and prevent scarring, which could help control VAs better. This review explains the usual treatments and explores the latest research on these innovative approaches for managing VAs.
Scientific Abstract:
Ventricular arrhythmias (VAs) represent a major cause of sudden cardiac death and afflict patients with heart failure from both ischaemic and non-ischaemic origins, and inherited cardiomyopathies. Current VA management, including anti-arrhythmic medications, autonomic modulation, implantable cardioverter-defibrillator implantation, and catheter ablation, remains suboptimal. Catheter ablation may even cause significant cardiomyocyte loss. Cell-based therapies and exosome treatment have been proposed as promising strategies to lessen cardiomyocyte death, modulate immune reaction, and reduce myocardial scarring, and, therefore, are potentially beneficial in treating VAs. In this review, we summarise the current cornerstones of VA management. We also discuss recent advances and ongoing evidence regarding cell-based and exosome therapy, with special attention to VA treatment.